Prosecution Insights
Prosecution Insights
3 pending office actions • 0 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Shenghe (China) Biopharmaceutical Co. Ltd. is currently managing 3 pending office actions. These 3 pending office actions are distributed among 3 distinct examiners, which indicates that the company is dealing with multiple examination styles. The data shows 0 distinct art units for this portfolio, which may suggest that the 3 pending office actions are not yet fully classified within the standard art unit system. This 0 distinct art units figure indicates a lack of centralized art unit oversight.
CUNNINGCHEN, KATHLEEN MARY is the busiest examiner for the company, currently managing 1 busiest examiner pending office action. This 1 busiest examiner pending action is a component of the workload that requires attention. With 3 distinct examiners involved, the applicant must manage different prosecution styles simultaneously. Practitioners should prepare for varied feedback from the assigned officials, as the lack of a common art unit baseline may lead to varied outcomes across the 1 busiest examiner pending action handled by CUNNINGCHEN, KATHLEEN MARY.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (67%) |
| Double-patenting + other | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CUNNINGCHEN, KATHLEEN MARY | 1 | 61.1% | +62.5% |
| CARTER, SANDRA DILLAHUNT | 1 | 56.2% | +29.0% |
| LUNDE, GRACE HENRY | 1 | 63.0% | +38.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18694554 | HETERODIMERIC PROTEIN AND APPLICATION THEREOF | CUNNINGCHEN, KATHLEEN MARY | — |
| 18576215 | ANTI-CD24 ANTIBODY AND USE THEREOF | LUNDE, GRACE HENRY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18694554 | HETERODIMERIC PROTEIN AND APPLICATION THEREOF | CUNNINGCHEN, KATHLEEN MARY | — |
| 18293500 | MULTISPECIFIC ANTIGEN-BINDING PROTEIN AND USE THEREOF | CARTER, SANDRA DILLAHUNT | — |
| 18576215 | ANTI-CD24 ANTIBODY AND USE THEREOF | LUNDE, GRACE HENRY | — |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18694554 | HETERODIMERIC PROTEIN AND APPLICATION THEREOF | CUNNINGCHEN, KATHLEEN MARY | — | §101§102§103§112 | Non-Final OA | — | Pending | Mar 22, 2024 |
| 18293500 | MULTISPECIFIC ANTIGEN-BINDING PROTEIN AND USE THEREOF | CARTER, SANDRA DILLAHUNT | — | §102§112DP | Non-Final OA | — | Pending | Jan 30, 2024 |
| 18576215 | ANTI-CD24 ANTIBODY AND USE THEREOF | LUNDE, GRACE HENRY | — | §101§102§112DP | Non-Final OA | — | Pending | Jan 03, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial